Skip to main content

Table 3 Main COVID-19 positive patients’ characteristics

From: Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice

Sex
 Male 11 (84.6%)
 Female 2 (15.4%)
Age
 Median 69.7 years (range 59.7–84.9)
 Mean 69.8 years
ECOG Performance Status
 PS0 3 (23.1%)
 PS1 8 (61.5%)
 PS2 0 (0%)
 PS3 2 (15.4%)
Smoking habit
 Smoker 9 (69.2%)
 Former smoker (15.4%)
 Non smoker (15.4%)
Comorbidities
 Arterial hypertension 4 (30.7%)
 Other cardiovascular diseases 6 (46.2%)
 Arrhytmias 2 (15.4%)
 Diabetes 2 (15.4%)
 Infectious diseases 2 (15.4%)
 Gastrointestinal diseases 2 (15.4%)
Number of comorbidities
 None 1 (7.7%)
 One 4 (30.8%)
 Two 3 23.1%
 Three or more 5 (38.5%)
Tumor diagnosis
 NSCLC 8 (61.5%)
 Head and neck SCC 2 (15.4%)
 Multiple myeloma 1 (7.7%)
 Breast cancer 1 (7.7%)
 Rectal cancer 1 (7.7%)
Tumor stage
 Stage IV 4 (30.8%)
 Stage III 7 (53.8%)
 Stage II 1 (7.7%)
 Unknown 1 (7.7%)
Ongoing treatment
 Radical or adjuvant/neoadjuvant radiotherapy 6 (46.2%)
 Palliative radiotherapy 4 (30.8%)
 Chemotherapy 4 (30.8%)
 Immunotherapy 2 (15.4%)
Treatment suspension
 No 6 (46.2%)
 Temporary 1 (7.7%)
 Definitive 6 (46.2%)
Chest radiograph
 Positive 11 (84.6%)
 Negative 2 (15.4%)
Chest CT scan
 Positive 6 (46.2%)
 Negative 0
 Not performed 7 (46.2%)
COVID-19 treatment
 Hydroxychloroquine 11 (84.6%)
 Lopinavir/ritonavir 8 (61.5%)
 Other antivirals 3 (23.1%)
 Tocilizumab 3 (23.1%)
 Azitromicin 9 (69.2%)
 No treatment 2 (15.4%)
Respiratory support
 Supplemental oxygen 10 (76.9%)
 Non-invasive ventilation 1 (7.7%)
 Invasive ventilation 0
COVID-19 outcome
 Negativized 6 (46.2%)
 Alive positive 2 (15.4%)
 Deceased 5 (38.5%)
  1. ECOG Eastern Cooperative Oncology Group, NSCLC Non Small Cell Lung Cancer, SCC Squamous Cell Carcinoma